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Clinical trial registration: NCT01009970Abstract
The purpose of this phase 2, multicenter study was to determine the activity and safety of nonpegylated liposomal doxorubicin as part of “R‐
COMP” combination in patients with diffuse large B‐cell lymphoma and coexisting cardiac disorders. The study was conducted using a Bayesian
continuing assessment method using complete remission rate and rate of cardiac events as study endpoints. Between November 2009 and
October 2011, 50 evaluable patients were enrolled (median age, 76 years). Median baseline left ventricular ejection fraction (LVEF) was
60%. Ischemic cardiopathy was the most frequent preexisting cardiac disorder (35%), followed by atrial fibrillation (15%), left ventricular hyper-
trophy (13%), and baseline LVEF <50% (12%). Based on the intent to treat analysis, overall response rate was 72%, including 28 patients in
complete remission (complete remission rate, 56%), and 8 in partial remission (16%). At the end of treatment, grades 3 to 4 cardiac events were
observed in 6 patients. No significant modifications from baseline values of LVEF were observed during treatment and follow‐up.Hematological Oncology. 2017;1–8. Copyright © 2017 John Wiley & Sons, Ltd.wileyonlinelibrary.com/journal/hon 1
2 LUMINARI ET AL.Nonpegylated liposomal doxorubicin instead of doxorubicin in the R‐CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and pred-
nisone) regimen is a feasible option for patients with diffuse large B‐cell lymphoma presenting with concomitant cardiac disorders.
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Diffuse large B‐cell lymphoma (DLBCL) is the most common subtype
of non‐Hodgkin lymphomas,1 typically affects elderly patients and
can be cured in 60% to 70% of cases with the standard R‐CHOP
immunochemotherapy.2,3 Conventional anthracyclines are the active
backbone of standard R‐CHOP, but cardiotoxicity related to the cumu-
lative dose may contraindicate or limit their use especially in patients
with preexisting or concomitant cardiac disorders.4 It has also been
shown that cardiotoxicity was the predominant late chemotherapy‐
related complication in long‐term survivors with aggressive lym-
phoma.5 However, cardiotoxicity data in patients with DLBCL are frag-
mentary and derive from relatively small studies, since patients older
than 65, whose age‐associated comorbidities may confer a higher risk
of anthracycline cardiotoxicity, are often excluded from clinical trials.6
Strategies to improve the cardiac safety of conventional
anthracyclines include alterations of dosing schedules to modify phar-
macokinetics,7 use of other conventional anthracyclines that may be
less cardiotoxic, administration of cardioprotective agents,8 and
administration of anthracyclines in liposome‐encapsulated. In particu-
lar, the use of nonpegylated liposomal doxorubicin (NPLD) is associ-
ated with reduced myelosuppression,9 reduced gastrointestinal
toxicity,10 and a reduced risk of cardiotoxicity11 compared with stan-
dard formulations. A phase III randomized trial that compared NLPD
and cyclophosphamide with doxorubicin and cyclophosphamide in
patients with metastatic breast cancer revealed significantly reduced
cardiotoxicity in the NLPD arm, without reducing the efficacy of
therapy.12 The toxicity and activity of NPLD when substituted for
conventional doxorubicin in the CHOP regimen (so‐called “R‐COMP”
regimen) have been evaluated also in the treatment of patients
with newly diagnosed aggressive non‐Hodgkin lymphomas, and the
combination has been found to be an effective and relatively well
tolerated regimen,13,14 even in patients with concurrent cardiac
diseases or prior anthracyclines exposure.15 On this background, we
designed a multicenter, single‐arm phase II trial addressing the activity
and safety of the R‐COMP combination as upfront treatment for
patients with DLBCL who had concomitant or pre‐existing cardiovas-
cular disorders (CDs).2 | METHODS
2.1 | Study design and eligibility criteria
This is an open label, single‐arm, multicenter phase II trial evaluating
the safety and efficacy of replacing doxorubicin with NLPD in standard
R‐CHOP in patients with newly diagnosed DLBCL and concomitant orpreexisting cardiac disorders. Selection criteria were (1) biopsy‐con-
firmed CD20 + DLBCL or follicular grade III b; (2) age ≥ 18 years; (3)
at least one of the following preexisting or concomitant CDs: left ven-
tricular ejection fraction (LVEF) <50%, left ventricular hypertrophy
(septal wall and/or posterior wall thickness > 1.2 cm), moderate to
severe high blood pressure not controlled by therapy, documented
ischemic heart disease, significant ventricular arrhythmias (score 3
according to the Lown grading system16), chronic atrial fibrillation, pul-
monary hypertension (mean estimating Pulmonary Artery Pressure
(mPAP) > 45 mmHg), moderate to severe mitral valve disease, and
moderate aortic valve disease (mean pressure gradient, 20‐40 mm
Hg). The Baseline CDs were categorized into 3 groups: electrical,
including heart rhythm disorders (arrhythmias and atrial fibrillation);
circulatory, including high blood pressure, ischemic heart disease, and
pulmonary hypertension; structural, including reduced LVEF, ventricu-
lar hypertrophy and valve disease. All patients were evaluated by Com-
prehensive Geriatric Assessment, including Activities of Daily Living,
Instrumental Activities of Daily Living, Cumulative Illness Rating Scale.
Activities of Daily Living =6, Instrumental Activities of Daily Living ≥4,
a maximum of 2 grade‐2 extra‐cardiac comorbidities and absence of
grade‐3 extra‐cardiac comorbidities, and no geriatric syndrome were
required for patients aged 70 years or older. Other inclusion criteria
were serum creatinine levels <2.5 mg/dL, bilirubin ≤ twice upper the
normal range, negative serology for hepatitis B, hepatitis C, and HIV.
Any stage and IPI score were considered.2.2 | Evaluations
Baseline assessment included disease history, B symptoms, physical
examination, laboratory assessments, contrast enhanced computed
tomography (CT) scan, electrocardiogram and cardiac examination, bi‐
dimensional echocardiogram (2D‐ECD), and bone marrow biopsy.
17Fluorodeoxyglucose‐positron emission tomography was recom-
mended at baseline. Cardiac function was assessed before treatment
start and was monitored after 3 cycles, at the end of therapy and dur-
ing follow‐up with 12‐leads electrocardiogram and with bi‐dimensional
echocardiogram. Bi‐dimensional echocardiogram had to be performed
locally at each referring center; no routine assessment of serum cardiac
troponin or B‐type natriuretic peptide was required by the study pro-
tocol. Final response had to be assessed in all evaluable patients by
contrast enhanced CT, positron emission tomography–CT scans, and
every procedure positive at baseline. During follow‐up, patients were
clinically evaluated every 3 months for 2 years and then every
6 months for 1 year, with restaging CT imaging at months 6, 12, 24,
and 36 from the end of the treatment.
This study was conducted according to the Good Clinical Practice
guidelines and the October 2000 revision of the Declaration of
LUMINARI ET AL. 3Helsinki. The study protocol was approved by the ethic committees
according to local rules. All patients gave their written informed con-
sent to participate before study entry. Patient registration and data
collection were realized using a dedicated web platform.TABLE 1 Patients characteristics
Variable N % Missing N (%)
Age
Median 76
Range 53‐90 ‐
>60 47 94
Sex, M 35 70 ‐
Stage
I‐II 19 38 ‐2.3 | Treatment
The R‐COMP regimen consisted of a standard R‐CHOP, replacing
doxorubicin with the same doses of NPLD (cyclophosphamide
750 mg/m2, day 1; vincristine 1.4 mg/m2 maximum dose of 2 mg,
day 1; NPLD 50 mg/m2, day 1; and prednisone 100 mg/day, days 1‐
5; rituximab 375 mg/m2, day 3 of cycle 1 and day 1 of subsequent
cycles). The NPLD (Myocet) was provided for free by the manufac-
turer. The R‐COMP had to be delivered on an outpatient basis every
3 weeks for 4 cycles in patients with stage I to II non‐Bulky disease
and for 6 cycles in all other patients.
Patients were treated with supportive medications, including pro-
phylactic antibiotics and antiemetic agents, according to physician's
discretion. Granulocyte colony‐stimulating factor was administered as
per institutional guidelines. In case of peripheral neuropathy, vincris-
tine doses could be reduced or withdrawn. Patients at risk of central
nervous system relapse received intrathecal doses of 12 mg metho-
trexate on day 1 of each cycle.18
The R‐COMP was interrupted in case of grades 3 to 4
nonhematologic toxicity causing treatment delay of more than 3 weeks
or for LVEF decrease of 20% from baseline or absolute 10 points in
LEVF from baseline.III‐IV 31 62
PS > 1 7 14 ‐
LDH > UNL 23 51 5 (10)
ENS > 1 5 10 ‐
Bulkya 5 10 1 (2)
IPI
0‐1 11 24
2 16 26 5 (10)
3‐5 18 40
Cardiac disorders
Ischemic cardiopathy 21 35
Atrial fibrillation 9 15
Left ventricular hypertrophy 8 13
LVEF <50% 7 12
Ventricular arrhythmia 5 8 ‐
Moderate/severe mitral valve disease 3 5
Moderate aortic valve disease 3 5
Pulmonary hypertension 2 3
Uncontrolled hypertension 2 3
Altered ECG 27 59 4 (8)
LVEF
Median 60 ‐ 3 (6)
IQR 12
Abbreviations: ECG, echocardiogram; ENS, extra nodal site; IPI, interna-
tional prognostic index; IQR, interquartile range; LDH, lactate dehydroge-
nase; LVEF, left ventricular ejection fraction; M, male; PS, performance
status; UNL, upper normal value.
aBulky = mediastinic >6 cm, lymph node >10 cm.2.4 | Statistics
The primary end points of this phase II study were the complete remis-
sion rate (CRR) and the rate of cardiac events (CEs). Responses were
assessed using the 2007 International Harmonization Project
criteria.17
Cardiac events were defined as LVEF decrease ≥20% from base-
line or absolute LVEF <25% at the end of treatment or clinical evidence
of heart failure. The coprimary end point analyses were performed for
all eligible patients according to an intent to treat principle.
The study enrollment and monitoring was planned according to a
Bayesian sequential analysis, considering a reference CRR of 65%19
and CEs rate of 15%.20 We planned to recruit a total of 55 patients,
also considering a dropout rate of about 10% to reach 50 eligible
patients. The a priori probability of CR and CEs were modeled by a
beta distribution, with parameters B(1.32; 0.68) for efficacy and
B(0.32; 1.68) for the safety. The trial was monitored by cohorts of 10
patients, and the study had to be interrupted if the observed response
rate was lower than the reference CR, with a posterior probability
greater than 95% (or more responsive with a posterior distribution
lower than 0.05) or if the observed rate of CEs was higher than the ref-
erence, with a posterior probability greater than 0.95.
The final CRR and CEs were reported with the exact Clopper‐
Pearson confidence interval limits (CIs) and as posterior 95% credible
interval. The paired comparison between baseline and end of treat-
ment LVEF was calculated using the Wilcoxon matched pairs signed‐
rank test.The secondary end points were overall response rate (ORR), pro-
gression‐free survival (PFS), and overall survival (OS).
Adverse events were categorized and graded according to the
National Cancer Institute Common Terminology Criteria for Adverse
Events (version 3.0).3 | RESULTS
3.1 | Patients
Between November 2009 and October 2011, 51 patients were
enrolled. One patient was subsequently excluded due to a violation
of the inclusion criteria. Sixty CDs were identified at baseline; 2 and
3 concomitant CDs were described in 4 and 3 patients respectively.
Baseline patients characteristics are shown in Table 1.
4 LUMINARI ET AL.3.2 | Feasibility and efficacy
The R‐COMP was started in all 50 patients; 49 patients (98%) received
at least 3 cycles and 38 (76%) completed the treatment receiving 6
courses (N = 30), or 4 courses of R‐COMP (N = 8) if they had a localized
disease at stage I to II according to trial protocol. Treatment was
interrupted prematurely in 12 cases due to adverse events (N = 10),
progressive disease (N = 1), or patient decision (N = 1).
Overall, 261 cycles of R‐COMP were delivered. All but 68 cycles
were administered on time: median delay was 3 days (range 1 to 28).
Dose reductions were adopted in 22 patients and in 68 cycles. The
NPLD was reduced in 13 cases and in 37 cycles. The mean calculated
dose intensity for all cycles of cyclophosphamide, NPLD, vincristine,
and rituximab were 92.2%, 90.6%, 89.6%, and 95.6%, respectively.
Based on the intention to treat analysis, 28 patients achieved a CR
at the end of therapy (56%; 95%CI, 41%‐70%), and 36 patients had an
objective response (ORR = 72%; 95%CI, 58% to 84%) (Table 2). As
requested by the sequential Bayesian monitoring, the CR rate never
fell outside activity boundaries (Figure 1a in the Supporting informa-
tion), thus the study achieved its main planned activity result.
The median follow‐up was 33 months (range 1‐61). Regarding the
definition of PFS, 30 events were reported including 11 progressions,
12 relapses, and 7 deaths for causes unrelated with lymphoma. Median
PFS was 17 months (95% CI; 9‐NA months). Progression‐free survival
at 3 years was 38% (95%CI; 24%‐51%) (Figure 1A).
Overall, 22 patients died, 6 during the treatment or within
3 months from treatment completion (2 due to lymphoma progression
and one each due to acute renal failure, acute liver failure, cerebral
hemorrhage, and pneumonia), and 16 during the follow‐up phase
(7 due to lymphoma progression, 2 each due to heart failure and severe
infection, one each due to respiratory failure, cachexia not related with
lymphoma, and lung cancer; in 2 cases, the cause of death was
unknown). Median age of patients died for causes unrelated to lym-
phoma progression was 78 years (range 70‐84). As a result, OS at
3 years was 50% (95%CI; 33%‐65%) (Figure 1B).
3.3 | Safety
Safety analysis was available for all 50 patients and for 248 cycles.
Neutropenia was the most common hematologic event, with gradesTABLE 2 Summary of study end points (N = 50)
Response N % (95CI)
CR 28 56 (41‐70)
PR 8 16 (4‐29)
ORR 36 72 (58‐84)
SD/PD 10 20 (10‐34)
NA/EW 4 8 (2‐19)
3‐yr survival # events % (95CI
OS 22 50 (34‐65)
PFS 30 38 (24‐51)
FFS 36 27 (15‐40)
Abbreviations: CI, confidence interval; CR, complete response; EW, early
withdrawal; FFS, failure free survival; NA, not assessed; ORR, overall
response rate; OS, overall survival; PD, progressive disease; PFS, progres-
sion free survival; PR, partial response; SD, stable disease.3 to 4 toxicity occurring in 64% of patients. Excluding cardiac toxicity,
grades 3 to 4 infections were the most common nonhematologic
adverse events (6%) (Table 3). Granulocyte colony‐stimulating factor
was used in 44 patients.3.4 | Cardiac events
Ten patients experienced 11 CEs during treatment that were graded as
3 to 4 in 6 cases (12%). Grades 3 to 4 CEs included 3 cases of LVEF
reduction ≥20% from baseline, 1 case each of congestive heart failure,
angina, and atrial fibrillation. In 1 case, LVEF decrease was also associ-
ated with an increase of troponin level (Table 4). Overall, study treat-
ment was discontinued due to the occurrence of CEs in 6 cases, all
occurred within the first 4 cycles (2 after cycle 3, and 3 after cycle
4). No patient died as a consequence of a CE; the remaining 4 patients
who experienced cardiac problems during study treatment continued
with the R‐COMP regimen, receiving an average of 5 courses (range
3‐6) and achieving CR in 2. As requested by the sequential Bayesian
monitoring, the CE rate never fell outside safety boundaries (as shown
in Figure 1b in the Supporting information), thus the study achieved
the predefined safety results.
Two patients died for congestive heart failure during the follow‐up
at 11 and 28 months from the last administration of R‐COMP,
respectively.
Considering LVEF monitoring, this was evaluated in 37 patients
with both assessments performed at baseline and end of therapy; in
13 cases, LVEF evaluation has not performed due to treatment inter-
ruption for toxicity (5) and for medical decision (2), due to unavailability
of patient (4), progression of disease (1), and loss to follow‐up (1). At
least 1 assessment during follow‐up was performed in 27 cases. We
observed a slight but not significant decrease from baseline to the
end of treatment of the median LVEF (measured reduction −4.0%,
P = .112) that remains stable during follow‐up (Figure 2). A significant
drop of LVEF was observed in individual cases.
We also analyzed the CE rates according to pretreatment CDs and
observed a trend of higher rate of CEs in the patients affected by elec-
trical disorders (30%) compared to the other 2 groups (circulatory and
structural disorders, with 16% and 7% CEs respectively; P = .227).
Three CEs (1 increased troponin, 2 LVEF drop ≥20%) occurred among
the 7 patients who were enrolled with a LVEF <50%.4 | DISCUSSION
In the HEART01 study, we investigated the activity and the safety of
the R‐COMP regimen in which conventional doxorubicin was
substituted with the same dose of NPLD for the treatment of patients
with DLBCL who also had one or more concomitant or preexisting car-
diac disorder. With 50 enrolled patients and with a median follow‐up
of 17 months, we were able to show a CR rate of 56%, a 3‐year PFS
of 38% and a 3‐year OS of 50% with manageable adverse events that
were mostly represented by severe neutropenia. Of note, the rate of
CEs during therapy was 21% with a 10% rate of severe events but
without any cardiac death during treatment. These activity and safety
results fulfilled the initially planned study assumption and allow us to
FIGURE 1 A, Progression free survival (PFS); B, overall survival (OS)
TABLE 3 Summary of clinical relevant adverse events occurred
Adverse event
Population (N = 50)
Any grade (%) Grades 3–4 (%)
Blood and lymphatic system disorders
Neutropenia 78 64
Anemia 88 46
Thrombocytopenia 58 8
Febrile neutropenia 2 2
Gastrointestinal disorders
Constipation 6 ‐
Nausea 6 2
Diarrhea 2 ‐
Abdominal pain 2 ‐
Vomiting 4 ‐
Stomatitis 4 ‐
Infections 22 6
General disorders
Pyrexia 4 ‐
Asthenia 10 2
Nervous system disorders
Paresthesia 18 0
TABLE 4 Summary of cardiac events during treatment
Population (N = 50)
Cardiac disorder Grades 1‐2, n (%) Grades 3‐4, n (%)
Heart failure 1(2) 1(2)
LVEF drop ≥20% 2(4)a 3(6)
Increased troponin 2(4) ‐
Angina ‐ 1(2)
Atrial fibrillation ‐ 1(2)
Tot 5(10) 6(12)
Abbreviations: LVEF, left ventricular ejection fraction.
aAsymptomatic.
LUMINARI ET AL. 5conclude this study with positive results and to consider R‐COMP as a
safe and active treatment option in patients with DLBCL and
coexisting CDs.
Until now, NPLD has been evaluated in retrospective21,22 and in
prospective studies23-27 not selecting the patients with preexisting
heart disease. The NPLD activity and safety profile in patients with
contraindication to the use of conventional anthracyclines including
cardiac disorders have been assessed only in 1 study.15 More recently,
2 randomized studies compared the cardiotoxicity of NPLD with thatof conventional doxorubicin in 2 independent series of patients with
untreated DLBCL.28,29 Both studies included patients with normal car-
diac function and were not able to show significant differences in the
low observed rate of CEs between conventional doxorubicin
and NPLD, also if safety signals were elevated in R‐CHOP compared
to R‐COMP.
Of note, this prospective study evaluated the feasibility of a full
dose chemoimmunotherapy regimen in a patient population that due
to the presence of one or more CD would not have been considered
eligible for a curative approach. The feasibility of the R‐COMP regimen
was confirmed with 76% of patients who were able to complete the
planned therapy and with a very high mean dose intensity, also includ-
ing NPLD. Of note, none of CEs that occurred during treatment
resulted in patients' death. Our results should be compared with the
study by Fields et al. that similarly included patients with coexisting
CDs and substituted doxorubicin with gemcitabine within the R‐CHOP
chemotherapy backbone.30 Although response rates and survival were
comparable between the 2 studies, Fields et al. apparently included
patients with more severe coexisting CDs; this might explain the
FIGURE 2 Left ventricular ejection fraction
trend from baseline to end of follow up
6 LUMINARI ET AL.higher rates of severe CEs (16%), and the 3 deaths occurred during
treatment due to CEs. Also, if a formal comparison is not appropriate
with other available clinical trials on DLBCL,2 our results look slightly
worse if compared with a reference 3‐year OS of 70% for patients with
DLBCL and with a similar age and confirm that patients with DLBCL
and CDs as defined in our study or with contraindication to the use
of anthracyclines represent a “hard to treat” population.30,31
In addition to the small sample size that is typical for a phase II
study, our results could be influenced by the initial definition of the
cardiac events that was based on a pragmatic approach and included
most of the conditions that would have caused a reduction of the
anthracycline dose if present. Considering the mechanism of
anthracycline‐induced cardiac toxicity, we acknowledge that the actual
risk of doxorubicin induced cardiac toxicity can vary among patients
with different cardiac conditions. In an exploratory analysis, we found
that the CE rate was increasingly high comparing patients with electri-
cal disorders to those with circulatory and structural disorders. In
patients with structural disorders, the risk of experiencing CE is low.
In contrast, in patient with low baseline LVEF, the CE rate is still high
also if an NPLD is administered in place of conventional doxorubicin.
Thus, the HEART01 study suggests that among patients with CD, the
contraindication to the use of doxorubicin may change according to
the quality of CD. In particular in patients at very high risk of CE, it is
likely that the use of NPLD is not safe enough, and different strategies
should be considered to preserve cardiac function and to allow the
administration of oncologic therapy with curative intent. The use
of doxorubicin‐free regimens might represent a good option30,31
or, if doxorubicin containing regimens are used, prevention of
anthracycline‐induced cardiotoxicity could be considered before
chemotherapy start. An accurate pretreatment cardiac evaluation
could provide treatment of modifiable risks factors and optimize the
cardiological therapy.
In conclusion, the HEART01 trial provides evidence of the feasibil-
ity and activity of the use of NPLD in patients with DLBCL and moder-
ate/severe cardiac comorbidity. There are very few available studies
with similar inclusion criteria, and patient with CDs are usually
excluded from the large randomized trials. Nonetheless, patient with
CC are frequently seen in daily practice, and based on currentlyavailable guidelines, no clear recommendation can be done, but the
use of anthracyclines is usually vaguely contraindicated.
The explored strategy resulted in a feasible and active
anthracycline‐containing regimen, maintaining the curative intent of
treatment in unfit, high‐risk patients. This trial sets the reference
activity and toxicity values for future studies willing to investigate
new approaches in a similar setting.AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF
INTEREST
SL has served as consultant for Roche, Celgene, and Teva (Formerly
Cephalon), has received an honoraria from Pfizer. FZ has received
research funding from GSK, Novartis, and Celgene and has received
honoraria from GSK, Novartis, Roche, Janssen, Takeda, Mundipharma,
Gilead, and Celgene. MS has served on advisory board and on
speakers' bureau, and he has received travel/accommodation from
Teva (Formerly Cephalon). AJMF is a member of advisory boards of
Acerta, Celgene, Gilead, Italfarmaco, and Mundipharma, received
grants supporting the own clinical research from Celgene, and
Mundipharma, and was invited speaker in meeting organized by
Adienne, Gilead, Mundipharma, and Italfarmaco. All remaining authors
have declared no conflicts of interest.
ACKNOWLEDGEMENTS
We thank all the patients who participated in this study and their
supportive families. We also thank the referring physicians and the
supporting staff at all the participating clinical sites. We thank all the
principal investigators of the other sites involved in this study: Maura
Brugiatelli (Messina), Salvatrice Mancuso (Palermo), Nicola Cascavilla
(S. Giovanni Rotondo), and Graziella Pinotti (Varese).
FUNDING
This work was supported by Cephalon that provided the Fondazione
Italiana Linfomi with NPLD, but was not involved in the study protocol,
data acquisition, data analysis or the writing of the paper. There is no
grant number.
LUMINARI ET AL. 7AUTHORS' CONTRIBUTIONS
EV, AT, FS, and MS designed the research study. All authors contrib-
uted to patient enrolment. SL analysed the data, performed the statis-
tical analyses, and wrote the first draft of the article. All authors
contributed to data interpretation, reviewed the draft, and approved
the final version.
REFERENCES
1. Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008
WHO classification of lymphoid neoplasms and beyond: evolving con-
cepts and practical applications. Blood. 2011;117(19):5019‐5032.
https://doi.org/10.1182/blood‐2011‐01‐293050
2. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab
compared with CHOP alone in elderly patients with diffuse large‐B‐cell
lymphoma. N Engl J Med. 2002;346(4):235‐242.
3. HabermannTM, Weller EA, Morrison VA, et al. Rituximab‐CHOP versus
CHOP alone or with maintenance rituximab in older patients with dif-
fuse large B‐cell lymphoma. J Clin Oncol. 2006;24(19):3121‐3127.
4. Lipshultz SE, Lipsitz SR, Mone SM, et al. Female sex and drug dose as
risk factors for late cardiotoxic effects of doxorubicin therapy for child-
hood cancer. N Engl J Med. 1995;332(26):1738‐1743. https://doi.org/
10.1056/NEJM199506293322602
5. Andre M, Mounier N, Leleu X, et al. Second cancers and late toxicities
after treatment of aggressive non‐Hodgkin lymphoma with the ACVBP
regimen:a GELA cohort study on 2837 patients. Blood. 2004;103(4):
1222‐1228.
6. Hutchins LF, Unger JM, Crowley JJ, Coltman CA Jr, Albain KS. Under-
representation of patients 65 years of age or older in cancer‐
treatment trials. N Engl J Med. 1999;341(27):2061‐2067. https://doi.
org/10.1056/NEJM199912303412706
7. van Dalen EC, van der Pal HJ, Caron HN, Kremer LC. Different dosage
schedules for reducing cardiotoxicity in cancer patients receiving
anthracycline chemotherapy. Cochrane Database Syst Rev. 2009;4:
CD005008. https://doi.org/10.1002/14651858.CD005008.pub3
8. van Dalen EC, Caron HN, Dickinson HO, Kremer LC. Cardioprotective
interventions for cancer patients receiving anthracyclines. Cochrane
Database Syst Rev. 2008;2:CD003917. https://doi.org/10.1002/
14651858.CD003917.pub3
9. Swenson CE, Bolcsak LE, Batist G, et al. Pharmacokinetics of doxorubi-
cin administered i.v. As Myocet (TLC D‐99; liposome‐encapsulated
doxorubicin citrate) compared with conventional doxorubicin when
given in combination with cyclophosphamide in patients with metasta-
tic breast cancer. Anticancer Drugs. 2003;14(3):239‐246. https://doi.
org/10.1097/01.cad.0000060626.61556.da
10. Ewer MS, Martin FJ, Henderson C, Shapiro CL, Benjamin RS, Gabizon
AA. Cardiac safety of liposomal anthracyclines. Semin Oncol. 2004;
31(6 Suppl 13):161‐181.
11. Allen TM, Martin FJ. Advantages of liposomal delivery systems for
anthracyclines. Semin Oncol. 2004;31(6 Suppl 13):5‐15.
12. Batist G, Ramakrishnan G, Rao CS, et al. Reduced cardiotoxicity and
preserved antitumor efficacy of liposome‐encapsulated doxorubicin
and cyclophosphamide compared with conventional doxorubicin and
cyclophosphamide in a randomized, multicenter trial of metastatic
breast cancer. J Clin Oncol. 2001;19(5):1444‐1454.
13. Luminari S, Montanini A, Caballero D, et al. Nonpegylated liposomal
doxorubicin (MyocetTM) combination (R‐COMP) chemotherapy in
elderly patients with diffuse large B‐cell lymphoma (DLBCL): results
from the phase II EUR018 trial. Ann Oncol. 2010;21(7):1492‐1499.
https://doi.org/10.1093/annonc/mdp544
14. Zaja F, Tomadini V, Zaccaria A, et al. CHOP‐rituximab with pegylated
liposomal doxorubicin for the treatment of elderly patients with diffuse
large B‐cell lymphoma. Leuk Lymphoma. 2006;47(10):2174‐2180.
https://doi.org/10.1080/1042819060079994615. Rigacci L, Mappa S, Nassi L, et al. Liposome‐encapsulated doxorubicin
in combination with cyclophosphamide, vincristine, prednisone
and rituximab in patients with lymphoma and concurrent cardiac
diseases or pre‐treated with anthracyclines. Hematol Oncol. 2007;
25(4):198‐203. https://doi.org/10.1002/hon.827
16. Lown B, Wolf M. Approaches to sudden death from coronary heart dis-
ease. Circulation. 1971;44(1):130‐142.
17. Cheson BD. The international harmonization project for response
criteria in lymphoma clinical trials. Hematol Oncol Clin North Am.
2007;21(5):841‐854.
18. Perez‐Soler R, Smith TL, Cabanillas F. Central nervous system
prophylaxis with combined intravenous and intrathecal methotrexate
in diffuse lymphoma of aggressive histologic type. Cancer. 1986;57(5):
971‐977.
19. Federico M, Dyer MJS, Caballero MD, Reilly C, Thiel E. The MYOCAN
study. a phase II study of cyclophosphamide, oncovin, Myocet, and
prednisone plus rituximab (R‐COMP) in the treatment of elderly
patients with diffuse large B‐cell non‐Hodgkin lymphoma (DLBCL).
Blood. 2004;104: abs 4586.
20. Limat S, Demesmay K, Voillat L, et al. Early cardiotoxicity of the CHOP
regimen in aggressive non‐Hodgkin's lymphoma. Ann Oncol. 2003;
14(2):277‐281.
21. Moreno M, Sancho J‐M, Gardella S, et al. Doxorrubicina liposomal no
pegilada en combinación con ciclofosfamida, vincristina, prednisona y
rituximab en el tratamiento de linfomas no hodgkinianos: estudio de
26 pacientes. Med Clin (Barc). 2010;134(2):72‐75. https://doi.org/
10.1016/j.medcli.2009.05.042
22. Mian M, Wasle I, Gamerith G, et al. R‐CHOP versus R‐COMP: are they
really equally effective? Clin Oncol. 2014;26(10):648‐652. https://doi.
org/10.1016/j.clon.2014.05.012
23. Visani G, Ferrara F, Alesiani F, et al. R‐COMP 21 for frail elderly
patients with aggressive B‐cell non‐Hodgkin lymphoma: a pilot study.
Leuk Lymphoma. 2008;49(6):1081‐1086. https://doi.org/10.1080/
10428190802043853
24. Gimeno E, Sánchez‐González B, Alvarez‐Larrán A, et al. Intermediate
dose of nonpegylated liposomal doxorubicin combination (R‐CMyOP)
as first line chemotherapy for frail elderly patients with aggressive lym-
phoma. Leuk Res. 2011;35(3):358‐362. https://doi.org/10.1016/j.
leukres.2010.07.024
25. Dell'Olio M, Scalzulli RP, Sanpaolo G, et al. Non‐pegylated liposomal
doxorubicin (Myocet®) in patients with poor‐risk aggressive B‐cell
non‐Hodgkin lymphoma. Leuk Lymphoma. 2011;52(7):1222‐1229.
https://doi.org/10.3109/10428194.2011.572321
26. Herrero J, Gómez‐Codina J, Provencio M, et al. Biweekly regimen of
nonpegylated liposomal doxorubicin with cyclophosphamide, vincris-
tine, and prednisone plus rituximab (R‐COMP‐14) as primary
treatment for diffuse large B‐cell lymphoma (DLBCL): Long‐term
follow‐up of a phase II study. J Clin Oncol. 2012;30(suppl): abs 8056.
27. Iannitto E, Luminari S, Mammi C, et al. Non‐Pegylated Lyposomal
doxorubicin, cyclophosphamide, vincristine, prednisone and rituximab
(R‐COMP) as initial treatment for patients with splenic marginal zone
lymphoma (SMZL). A GISL study. Blood. 2007;110: abs 1293.
28. Fridrik MA, Jaeger U, Petzer A, et al. Cardiotoxicity with rituximab,
cyclophosphamide, non‐pegylated liposomal doxorubicin, vincristine
and prednisolone compared to rituximab, cyclophosphamide, doxorubi-
cin, vincristine, and prednisolone in frontline treatment of patients with
diffuse large B‐. Eur J Cancer. 2016;58:112‐121. https://doi.org/
10.1016/j.ejca.2016.02.004
29. Sancho J‐M, Gual F, Fernández‐Alvarez R, et al. R‐COMP vs. R‐CHOP
as first‐line treatment for De Novo diffuse large B‐cell lymphoma in
patients older than 60 years: Preliminary results from a prospective
randomized phase 2 study from the Spanish group Geltamo. Blood.
2016;128: abs 5387.
30. Fields PA, Townsend W, Webb A, et al. De Novo treatment of
diffuse large B‐cell lymphoma with rituximab, cyclophosphamide,
vincristine, gemcitabine, and prednisolone in patients with cardiac
8 LUMINARI ET AL.comorbidity: a United Kingdom National Cancer Research Institute
Trial. J Clin Oncol. 2014;32(4):282‐287. https://doi.org/10.1200/
JCO.2013.49.7586
31. Rashidi A, Oak E, Carson KR, Wagner‐Johnston ND, Kreisel F, Bartlett
NL. Outcomes with R‐CEOP for R‐CHOP‐ineligible patients with dif-
fuse large B‐cell lymphoma are highly dependent on cell of origin
defined by Hans criteria. Leuk Lymphoma. 2016;57(5):1191‐1193.
https://doi.org/10.3109/10428194.2015.1096356
SUPPORTING INFORMATION
Additional Supporting Information may be found online in the
supporting information tab for this article.How to cite this article: Luminari S, Viel E, Ferreri AJM, et al.
Nonpegylated liposomal doxorubicin combination regimen in
patients with diffuse large B‐cell lymphoma and cardiac comor-
bidity. Results of the HEART01 phase II trial conducted by the
Fondazione Italiana Linfomi. Hematological Oncology. 2017.
https://doi.org/10.1002/hon.2425
